January 18, 2017 09:27 AM EST

Novartis chief Jimenez touts two top PhIII drug prospects

Arsalan Arif

Founder

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

Bayer starts 2025 by cutting 2,000 jobs as it homes in on year-end rehaul target

Some generics, biosimilar drugmakers say they can withstand tariff impact

UnitedHealth Group CEO Andrew Witty steps down

Updated: To spin off or not to spin off? Galapagos backpedals on separation plans, CEO Paul Stoffels exits early

Arcturus to prioritize mRNA therapeutics in bid to boost rare disease programs